CAMPBELL, CALIFORNIA | January 26, 2026 — Myra Vision, a Shifamed portfolio company, announced that the first patient has been treated in its U.S. ADAPT clinical study, evaluating the Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System in patients with glaucoma. The initial procedure was performed by Dr. David Godfrey at Glaucoma Associates of Texas, marking a critical milestone in the company’s FDA-regulated Investigational Device Exemption (IDE) pathway and advancing the clinical evaluation of an adjustable glaucoma shunt designed for personalized intraocular pressure (IOP) management.
Science Significance
The scientific importance of this milestone lies in the introduction of titratable, postoperatively adjustable glaucoma therapy into U.S. clinical evaluation. Glaucoma progression is driven by elevated or poorly controlled intraocular pressure, yet current surgical interventions lack the ability to dynamically adapt to patient-specific needs over time. The Calibreye™ TGT Surgical System is designed to enable slit-lamp–based, noninvasive postoperative adjustment of aqueous outflow, allowing clinicians to fine-tune IOP reduction as disease progression or healing responses evolve. This approach represents a significant departure from static shunt and trabeculectomy designs, aligning device engineering with the biological variability observed in glaucoma patients.
Regulatory Significance
From a regulatory standpoint, treatment of the first patient signifies active execution of an FDA-approved IDE clinical study, transitioning Myra Vision from preclinical and feasibility phases into human clinical evaluation. The ADAPT study is a prospective, multicenter, open-label investigation enrolling up to 70 patients with refractory glaucoma, with a 12-month primary effectiveness endpoint. IDE studies are subject to stringent GCP-equivalent requirements for medical devices, including protocol adherence, safety monitoring, data integrity, and investigator oversight. For cGxP professionals, this milestone reflects regulatory readiness, validated manufacturing controls, and alignment with FDA expectations for novel implantable ophthalmic devices.
Business Significance
Advertisement
Strategically, enrolling the first patient materially advances Myra Vision’s U.S. commercialization trajectory. Clinical execution under IDE oversight is a prerequisite for future FDA submissions, and early procedural success supports investor confidence and strategic partnerships. As a portfolio company of Shifamed, Myra Vision benefits from an innovation model focused on de-risking device development and accelerating time to market. The ADAPT study positions the company within the high-value glaucoma surgery market, where demand continues to rise due to aging populations and increasing disease prevalence. Demonstrating clinical feasibility and effectiveness is essential for future reimbursement discussions and adoption by glaucoma specialists.
Patients’ Significance
For patients, the clinical implications are substantial. Glaucoma is the leading cause of irreversible blindness worldwide, affecting tens of millions of individuals, with no curative treatment available. Patients with moderate to advanced or refractory glaucoma often require surgical intervention when medications fail, yet existing options do not allow postoperative customization. A titratable glaucoma shunt offers the potential for safer, more precise, and individualized pressure control, reducing the risk of hypotony or insufficient IOP reduction. This patient-centric design aims to improve long-term visual outcomes while reducing the need for revision surgeries, addressing a critical unmet need in glaucoma care.
Policy Significance
At the policy level, the ADAPT study reflects FDA support for innovative medical devices addressing chronic, vision-threatening diseases. Adjustable implant technologies align with broader healthcare priorities emphasizing personalized medicine, long-term disease management, and outcome-driven care. Regulatory frameworks such as the IDE pathway enable responsible clinical innovation while maintaining patient safety, ensuring that emerging technologies are evaluated through rigorous, evidence-based processes. Successful development of titratable glaucoma therapies could influence future standards of care and regulatory guidance in ophthalmic device development.
The treatment of the first patient in Myra Vision’s ADAPT clinical study marks a pivotal step in the clinical and regulatory advancement of adjustable glaucoma therapy in the United States. By combining innovative device engineering with FDA-governed clinical execution, Myra Vision is addressing a long-standing limitation in glaucoma surgery—lack of postoperative flexibility. For the cGxP.wire audience, this development highlights how compliance-driven clinical research enables the translation of MedTech innovation into potential patient benefit, reinforcing the critical role of regulated clinical studies in advancing ophthalmic care.
Source: Myra Vision press release
